The Latest Breaking News from Novo Nordisk

Melissa Lee reports for ‘Big Shot: The Ozempic Revolution,’ debuting Feb. 29

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

J.P. Morgan thinks sales of weight-loss drugs could exceed $100 billion by 2030. That's good news for Eli Lilly, which is now the largest pharma company by market capitalization and the 9th-biggest S&P 500 stock. Here's why LLY stock looks poised to put on even more weight in the months…

Loss of muscle mass also flagged, as UK drugmaker works with China’s Eccogene on obesity and type 2 diabetes pill

Healthcare stocks LLY and NVO have crushed broader market returns in the past two decades. But with competition heating up over obesity drugs, which mega-cap stock is a better buy today?

Amgen stock slumped Monday — as Eli Lilly stock hit a record high — after the company unveiled preclinical results for its weight-loss drug.

Shares in Novo Nordisk rose after its parent, Novo Holdings, said it has agreed to by contract drug manufacturer Catalent for $11.5 billion in cash.

The stock market largely took a huge earnings week in stride, along with Fed chief Powell and a hot jobs report hitting rate-cut odds.

The Dow Jones rose Thursday on a surprise jump in initial unemployment claims. Magnificent Seven stocks Amazon and Apple will report late.

Amid rising global medical needs, an aging population, and technological advancements, the pharmaceutical industry is expected to witness robust growth over the coming years. Given this positive backdrop, let’s analyze the investment prospects of pharma stocks Madrigal (MDGL), Pfizer (PFE), Astellas (ALPMY), and Novo Nordisk (NVO). Read on.

The stock market weakened in afternoon trading on Wednesday following Fed chief Jerome Powell's comments Wednesday afternoon.